Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes: DPP-4 inhibition and glycaemic control
Year: 2006
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W1585447752
